Please Wait...

Rare Disease

Rare Disease New Developments

  • 0
  • 03 Jun
As a follow-up to my previous blog post on rare disease development in the pharmaceutical and biotech industry, here's a chart to show the increase in interest in applications since 1983, which was taken from the FDA website.
Read More

Growing Interest in Rare Disease for Pharma and Biotech Industry

  • 0
  • 01 Jun
At BioClinica, we are involved in a number of rare disease studies. This is a growing area of development for the pharmaceutical and biotech industry. FDA’s office of Orphan Product Development reports that they saw a record 323 orphan drug designation requests come through the door in 2010. It's unclear why – one reason could be OOPD's outreach efforts. Rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in Europe. It is estimated that in the United States, 47% of rare disorders affect fewer than 25,000 people. Because patient populations for rare diseases are so small, big pharmaceutical companies historically have had little financial incentive to invest in drug development for these diseases.
Read More

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (Yesterday)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (Yesterday)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (Yesterday)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (Yesterday)
Innovation Theater @DrugInfoAssn #DIA2017 Kicking off at 1. Perspectives on risk-based monitoring and TQM. https://t.co/mH6Npg0kD4
bioclinica (Yesterday)
RT @Xtalks: How Improving Site Payments Can Make You the Sponsor/CRO of Choice Tune in for this live webinar with @bioclinica https://t.co/…
bioclinica (Yesterday)

Latest Blogs: